NetScientific PLC (LON:NSCI) revealed that its portfolio company Vortex BioSciences has signed a collaboration deal with BioView Ltd, a provider of automated cell imaging and analysis solutions with the aim of providing clinicians with deeper insights into cancer biology.
The AIM-listed transatlantic biomedical and healthcare IP commercialisation group said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool.
BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions.
Francois Martelet, NetScientific's CEO and chairman of Vortex, said: “This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex’s platform.”
He concluded: “This technology has potential applications in the fast-evolving field of immuno-oncology and the collaboration represents a critical step for Vortex as it moves towards the clinical market.”